Edgewise Therapeutics (EWTX) Total Liabilities (2020 - 2026)

Edgewise Therapeutics has disclosed Total Liabilities across 7 years of filings, most recently posting $25.3 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $25.3 million, up 2.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $25.3 million (up 2.62% YoY), and the FY2025 annual result was $30.3 million, up 9.95% from the prior year.
• Total Liabilities came in at $25.3 million for Q1 2026 at Edgewise Therapeutics, down from $30.3 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $30.3 million in Q4 2025 to a low of $11.0 million in Q2 2022.
• The 5-year median for Total Liabilities is $21.2 million (2024), against an average of $21.1 million.
• Across the five-year window, Total Liabilities soared 155.39% in 2022 and climbed 2.62% in 2026, its largest moves.
• Edgewise Therapeutics' Total Liabilities stood at $20.4 million in 2022, then increased by 4.02% to $21.2 million in 2023, then surged by 30.16% to $27.6 million in 2024, then advanced by 9.95% to $30.3 million in 2025, then fell by 16.57% to $25.3 million in 2026.
• The last three Total Liabilities figures came in at $25.3 million (Q1 2026), $30.3 million (Q4 2025), and $24.8 million (Q3 2025), per Business Quant data.